Chunlizhengda Seeks Mandate for Up to 10% H-Share Buyback

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H ( (HK:1858) ) has provided an update. Beijing Chunlizhengda Medical Instruments has called a class meeting of its H-shareholders for 26 May 2026 in Beijing, to be held immediately after the 2025 annual general meeting and the A-shareholders’ class meeting. The session will consider a special resolution to grant the board a general mandate to repurchase up to 10% of the company’s H shares outstanding at the time of approval. The proposed mandate would allow the board to determine specific repurchase terms, including pricing, volume and timing, in line with market conditions, funding needs and regulatory requirements in both the PRC and the markets where its shares are listed. It also authorises the board to handle all related procedures, from regulatory filings and foreign exchange arrangements to share cancellation, capital reduction and amendments to the articles of association, potentially affecting capital structure and shareholder value. More about Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Beijing Chunlizhengda Medical Instruments Co., Ltd. is a PRC-incorporated joint stock company listed in Hong Kong via H shares. The company operates in the medical instruments sector, focusing on the design, production and sale of medical devices to healthcare providers in China and overseas capital markets. Average Trading Volume: 723,413 Technical Sentiment Signal: Sell Current Market Cap: HK$7.71B Find detailed analytics on 1858 stock on TipRanks’ Stock Analysis page.